This series features essays by Dr. Kenneth Serbin, Professor of History, originally posted on his blog, At Risk for Huntington's Disease."
Huntington's Disease (HD) is a genetically caused brain disorder that causes uncontrollable bodily movements and robs people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
Blog Posts from 2020
Striving to overcome the doom of Huntington’s disease, Kenneth P. Serbin
I’m a Huntington’s disease gene carrier at age 60, so why haven't I developed symptoms yet?, Kenneth P. Serbin
Planning a ‘Dancing at the Vatican’ screening to celebrate the global Huntington's disease community's journey, Kenneth P. Serbin
Blog Posts from 2019
An ‘electric,’ inspiring Thanksgiving for the Huntington's disease community, Kenneth P. Serbin
‘Navigating’ the Huntington’s disease community towards crucial clinical trials, Kenneth P. Serbin
Are we failing to stop Huntington’s disease by ignoring 'natural' remedies, alternative therapies, and repurposed drugs?, Kenneth P. Serbin
As range of possible therapies grows, CHDI expands efforts to defeat Huntington's disease, Kenneth P. Serbin
What if we could turn off the cause of Huntington’s disease?, Kenneth P. Serbin
Factor-H partners with Latin American organizations to aid destitute Huntington's disease families, seeks to expand support, Kenneth P. Serbin
‘Dancing at the Vatican,’ about Huntington’s families' remarkable papal audience, premieres July 27, Kenneth P. Serbin
Roche restarts redesigned Phase 3 Huntington’s disease trial, Kenneth P. Serbin
Are pre-existing conditions returning, and Obamacare ending?, Kenneth P. Serbin
My Huntington’s disease sister – and a hero who strives for the unthinkable, Kenneth P. Serbin
‘Let’s Talk About Huntington’s Disease’: 2019 HD Awareness Month kicks off, Kenneth P. Serbin
Comedian Rod Man’s heartfelt speech, Ramona Johnston's death remind us of urgent need to cure Huntington's disease, Kenneth P. Serbin
Roche: less frequent dosing for Phase 3 Huntington's clinical trial, easing burden on patients, Kenneth P. Serbin
Roche ramps up Huntington’s disease clinical trial for early-to mid-stage patients, considers ways to expand research, Kenneth P. Serbin
‘We can now fear Huntington’s disease less’: reflections on the 14th Therapeutics Conference, Kenneth P. Serbin
CHDI’s chief scientist: ‘Not a time for the Huntington's community to rest its laurels', Kenneth P. Serbin
Continued progress, but also caution, in the fight against Huntington's disease, Kenneth P. Serbin
Hacking humans, upgrading Homo sapiens: the role of the Huntington's disease community and the consequences for life, Kenneth P. Serbin
A friend of the Huntington’s community receives award for HD article in influential Brazilian magazine, Kenneth P. Serbin
Blog Posts from 2018
Roche announces U.S., Canada sites for Phase 3 clinical trial of Huntington's disease drug, Kenneth P. Serbin
Building solidarity in disease communities’ quest for better care and treatments: a conversation with a young tennis award-winner, Kenneth P. Serbin
This Thanksgiving, appreciating stable health and new plans for Huntington's disease advocacy, Kenneth P. Serbin